© 2020 MJH Life Sciences and Neurology Live. All rights reserved.
© 2020 MJH Life Sciences™ and Neurology Live. All rights reserved.
September 18, 2020
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 18, 2020.
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed the results of a phase 2 core and extension study of ponesimod in patients with relapsing-remitting multiple sclerosis.
Along with being generally well tolerated, ozanimod was able to help most patients become relapse free without disability progression.
September 17, 2020
The neurologist at Lenox Hill Hospital detailed the findings of his observational study that looked at patterns of COVID-19 infections in patients with multiple sclerosis.
Two posters presented at MS 2020 confirm satralizumab’s ability to reduce protocol-defined relapse including in patients with treatment-naïve NMOSD.
September 16, 2020
The executive vice president and head of global research and development at Atara Biotherapeutics spoke to the findings of a phase 1 study of the cell therapy ATA188.
September 15, 2020
Data show that higher CSF tau levels at diagnosis correlated with worse disability independent of age, though no such associations were identified with amyloid-beta.
September 14, 2020
Experts in multiple sclerosis review top data presented at the 8th joint ACTRIMS-ECTRIMS meeting.
No new safety signals were observed in the combined analysis of ponesimod from the phase 2b core study and extension study.
September 11, 2020
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 11, 2020.
Treatment-naïve patients showed consistent results with the overall study population that was observed in the ASCLEPIOS I and II trials.
Patients with relapsing multiple sclerosis and high levels of fatigue were less likely to be employed full-time than those with MS with low fatigue.